Skip to content
Open access

TNFAIP3/A20 dysfunction drives innate and sterile hyperinflammation

Jul 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 90 references
Medicine

TL;DR

It is suggested that in diseases caused by insufficient TNFAIP3/A20 activity, autoantibodies may reflect a downstream consequence of disease rather than a causative driver, suggesting autoinflammatory rather than autoimmune pathology.

Abstract

Feedback mechanisms regulate immune activation and prevent excessive tissue damage. TNFAIP3, also known as A20, serves as a crucial brake on inflammation, and mutations or haploinsufficiency of this gene are linked to diseases characterized by inappropriate inflammation. In this study, we document highly conserved patterns of cell type-specific gene expression, regulation, and induction of TNFAIP3, and employ transgenic and gnotobiotic mouse models to investigate how adaptive immunity and the gut microbiome contribute to pathology arising from impaired A20 function. Contrary to our expectations, systemic inflammation resulting from Tnfaip3 deficiency in CD11c (Itgax)-expressing cells developed independently of autoreactive antibodies, B cells, and T cells. The microbiome also proved dispensable for disease manifestations in these models. These findings suggest that in diseases caused by insufficient TNFAIP3/A20 activity, autoantibodies may reflect a downstream consequence of disease rather than a causative driver, suggesting autoinflammatory rather than autoimmune pathology. These insights carry therapeutic implications for the treatment of TNFAIP3-associated diseases.

Read PDF

Similar papers

Review Open access Jul 2026

The NLRP3 inflammasome as a dynamic context-dependent regulator: mechanisms, disease progression, and therapeutic implications.

This review examines NLRP3 biology across three interconnected dimensions: cellular context, including immune and non-immune compartments; microenvironmental context, including infectious versus sterile inflammation and tissue repair versus tissue damage; and disease context, including stage- and time-dependent functio...

Shuo Liu, Xun Liu, Jing Hu et al. · 0 citations
Open access Aug 2026

TL1A-DR3 Signaling in Inflammatory Bowel Disease: From Pathogenesis to Therapeutic Targeting.

Current evidence highlights TL1A blockade as a promising dual-pathway therapeutic approach targeting inflammation and fibrotic remodeling, with ongoing studies expected to define its long-term impact on disease modification.

Kozo Tsuruta, Shinichiro Yoshioka, Hidetoshi Takedatsu · 0 citations
Open access Aug 2026

OTUD5 maintains STAT1/2 stability and promotes IFNγ-driven intestinal inflammation

Using an intestinal epithelial cell -specific Otud5 KO mouse model, it is shown that Otud5 deficiency significantly alleviated the IFNγ-dependent colitis induced by dextran sulfate sodium, as evidenced by reduced weight loss and diminished infiltration of Ly6C+ inflammatory monocytes.

Huiyuan Guan, Changzhou Cai, Jiewei Wang et al. · 0 citations
Open access Jul 2026

NLRP3 confers regulatory T cell-mediated control of intestinal inflammation 2256029

A previously underappreciated anti-inflammatory role of NLRP3 in Tregs in controlling Th17 responses in the intestines is demonstrated and should guide effective therapies for intestinal disorders where the anti-inflammatory vs. proinflammatory role of NLRP3 is still debated.

Rasika Patkar, Justin Yip, Chia-Hao Lin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.